Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1246 to 1260 of 2011 results for nice guidelines

  1. Mersey Burns for calculating fluid resuscitation volume when managing burns (MIB58)

    NICE has developed a medtech innovation briefing (MIB) on Mersey Burns for calculating fluid resuscitation volume when managing burns

  2. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.

  3. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

  4. QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography (HTG571)

    Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.

  5. Evidence summaries: process guide (PMG31)

    This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance

  6. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)

    NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .

  7. Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause (TA1143)

    Evidence-based recommendations on fezolinetant (Veoza) for treating moderate to severe vasomotor symptoms associated with menopause.

  8. AI technologies for detecting diabetic retinopathy (MIB265)

    NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .

  9. Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia (HTG345)

    Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.

  10. Stopping preventive medicines:- What is the clinical and cost effectiveness of stopping preventive medicines in people with multimorbidity who may not benefit from continuing them?

    trials of the medium term (2–10 years) benefit of medicines recommended in guidelines for preventing future morbidity or mortality,...

  11. t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227)

    NICE has developed a medtech innovation briefing (MIB) on t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes .

  12. iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)

    NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .

  13. moorLDLS-BI for burn depth assessment (MIB251)

    NICE has developed a medtech innovation briefing (MIB) on moorLDLS-BI for burn depth assessment .

  14. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.

  15. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.